Article Text

other Versions

PDF
The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6- month results from a longitudinal, observational, multicenter study
  1. M S Heiberg (marte.schrumpf{at}diakonsyk.no)
  1. Diakonhjemmet Hospital, Norway
    1. C Kaufmann (cecilie.kaufmann{at}sb-hf.no)
    1. Buskerud Central Hospital, Norway
      1. E Rødevand (erik.rodevand{at}stolav.no)
      1. St. Olav Hospital, Norway
        1. K Mikkelsen (knut.mikkelsen{at}revmatismesykehuset.no)
        1. Lillehammer Hospital for Rheumatic Diseases, Norway
          1. W Koldingsnes (wenche.koldingsnes{at}unn.no)
          1. University Hospital Northern Norway, Norway
            1. P Mowinckel (pettermowi{at}hotmail.no)
            1. Diakonhjemmet Hospital, Norway
              1. T K Kvien (t.k.kvien{at}medisin.uio.no)
              1. Diakonhjemmet Hospital, Norway

                Abstract

                Objectives: To compare the response to treatment with tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) monotherapy in patients with psoriatic arthritis (PsA) within a real life clinical setting.

                Methods: We analyzed data from an ongoing longitudinal, observational multicenter study in Norway. Our data comprised 526 cases of patients with PsA who received either anti-TNF treatment (n = 146) or MTX monotherapy (n = 380) and were followed for at least 6 months with measures of disease activity, health status and utility scores. A propensity score was computed to adjust for channeling bias. The changes in measures of disease activity and health-related quality of life from baseline to 3- and 6-month follow-up were compared between the groups with adjustments for the baseline value of the dependent variable and the propensity score (analyses of covariance (ANCOVA)).

                Results: The groups were significantly different at baseline with respect to demographic and disease activity measures. The variables included in the propensity score were age, sex, number of previous disease modifying anti-rheumatic drugs (DMARDs), presence of erosive disease, treatment center and investigator's global assessment. The adjusted changes at 6 months were significantly larger in the anti-TNF group for ESR, DAS-28, M-HAQ, patient's assessments of pain, fatigue and global disease activity on a visual analogue scale (VAS) and 4 out of 8 SF-36 dimensions.

                Conclusions: Clinical improvement was superior with TNF inhibitors compared to MTX monotherapy in patients with PsA, when assessed in this setting of daily clinical practice.

                • TNF inhibitor
                • health-related quality of life
                • longitudinal observational study
                • methotrexate
                • psoriatic arthritis

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.